Bellicum Pharmaceuticals, Inc. (BLCM) formed inverse H&S with $9.49 target or 7.00% above today’s $8.87 share price. Bellicum Pharmaceuticals, Inc. (BLCM) has $294.97 million valuation. The stock increased 0.11% or $0.01 during the last trading session, reaching $8.87. About 245,010 shares traded. Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has risen 32.63% since January 11, 2017 and is uptrending. It has outperformed by 15.93% the S&P500.
Cerecor Incorporated (NASDAQ:CERC) had a decrease of 10.25% in short interest. CERC’s SI was 1.07 million shares in January as released by FINRA. Its down 10.25% from 1.19M shares previously. With 1.65M avg volume, 1 days are for Cerecor Incorporated (NASDAQ:CERC)’s short sellers to cover CERC’s short positions. The SI to Cerecor Incorporated’s float is 12.63%. The stock decreased 11.46% or $0.29 during the last trading session, reaching $2.24. About 453,877 shares traded. Cerecor Inc. (NASDAQ:CERC) has declined 81.69% since January 11, 2017 and is downtrending. It has underperformed by 98.39% the S&P500.
Among 10 analysts covering Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. Bellicum Pharmaceuticals Inc has $32 highest and $16.0 lowest target. $25.33’s average target is 185.57% above currents $8.87 stock price. Bellicum Pharmaceuticals Inc had 18 analyst reports since July 24, 2015 according to SRatingsIntel. Zacks downgraded the shares of BLCM in report on Wednesday, August 19 to “Hold” rating. As per Monday, June 12, the company rating was maintained by Jefferies. Guggenheim upgraded the shares of BLCM in report on Friday, September 11 to “Buy” rating. The firm has “Buy” rating by Citigroup given on Friday, July 24. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, June 23. The firm has “Buy” rating given on Friday, June 3 by SunTrust. The stock of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) earned “Buy” rating by Jefferies on Tuesday, September 12. The firm has “Sell” rating by Zacks given on Monday, September 21. Suntrust Robinson initiated the shares of BLCM in report on Friday, June 3 with “Buy” rating. The firm has “Buy” rating by Cantor Fitzgerald given on Wednesday, November 2.
Analysts await Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) to report earnings on March, 12. They expect $-0.69 EPS, up 6.76% or $0.05 from last year’s $-0.74 per share. After $-0.71 actual EPS reported by Bellicum Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -2.82% EPS growth.